These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26005802)

  • 1. Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome.
    Franken R; El Morabit A; de Waard V; Timmermans J; Scholte AJ; van den Berg MP; Marquering H; Planken NR; Zwinderman AH; Mulder BJ; Groenink M
    Int J Cardiol; 2015 Sep; 194():7-12. PubMed ID: 26005802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
    Groenink M; den Hartog AW; Franken R; Radonic T; de Waard V; Timmermans J; Scholte AJ; van den Berg MP; Spijkerboer AM; Marquering HA; Zwinderman AH; Mulder BJ
    Eur Heart J; 2013 Dec; 34(45):3491-500. PubMed ID: 23999449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
    Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
    J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between fibrillin-1 genotype and severity of cardiovascular involvement in Marfan syndrome.
    Franken R; Teixido-Tura G; Brion M; Forteza A; Rodriguez-Palomares J; Gutierrez L; Garcia Dorado D; Pals G; Mulder BJ; Evangelista A
    Heart; 2017 Nov; 103(22):1795-1799. PubMed ID: 28468757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.
    van Andel MM; Indrakusuma R; Jalalzadeh H; Balm R; Timmermans J; Scholte AJ; van den Berg MP; Zwinderman AH; Mulder BJM; de Waard V; Groenink M
    Eur Heart J; 2020 Nov; 41(43):4181-4187. PubMed ID: 32548624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aortic tortuosity in Turner syndrome is associated with larger ascending aorta.
    Srinivasan R; Shanbhag S; Pezzini A; Olivieri L; Morris SA
    Int J Cardiovasc Imaging; 2022 Nov; 38(11):2479-2490. PubMed ID: 36434337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
    De Backer J
    Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
    Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
    Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
    Milleron O; Arnoult F; Ropers J; Aegerter P; Detaint D; Delorme G; Attias D; Tubach F; Dupuis-Girod S; Plauchu H; Barthelet M; Sassolas F; Pangaud N; Naudion S; Thomas-Chabaneix J; Dulac Y; Edouard T; Wolf JE; Faivre L; Odent S; Basquin A; Habib G; Collignon P; Boileau C; Jondeau G
    Eur Heart J; 2015 Aug; 36(32):2160-6. PubMed ID: 25935877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does altered aortic flow in marfan syndrome relate to aortic root dilatation?
    Wang HH; Chiu HH; Tseng WY; Peng HH
    J Magn Reson Imaging; 2016 Aug; 44(2):500-8. PubMed ID: 26854646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
    Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
    Trials; 2010 Jan; 11():3. PubMed ID: 20067609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
    Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
    Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
    Kang YN; Chi SC; Wu MH; Chiu HH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.
    Mullen MJ; Flather MD; Jin XY; Newman WG; Erdem G; Gaze D; Valencia O; Banya W; Foley CE; Child A
    Trials; 2013 Dec; 14():408. PubMed ID: 24289736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aortic diameter predicts acute type A aortic dissection in patients with Marfan syndrome but not in patients without Marfan syndrome.
    Kim EK; Choi SH; Sung K; Kim WS; Choe YH; Oh JK; Kim DK
    J Thorac Cardiovasc Surg; 2014 May; 147(5):1505-10. PubMed ID: 23879932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice.
    Franken R; Hibender S; den Hartog AW; Radonic T; de Vries CJ; Zwinderman AH; Groenink M; Mulder BJ; de Waard V
    PLoS One; 2014; 9(9):e107221. PubMed ID: 25238161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.
    Franken R; den Hartog AW; Radonic T; Micha D; Maugeri A; van Dijk FS; Meijers-Heijboer HE; Timmermans J; Scholte AJ; van den Berg MP; Groenink M; Mulder BJ; Zwinderman AH; de Waard V; Pals G
    Circ Cardiovasc Genet; 2015 Apr; 8(2):383-8. PubMed ID: 25613431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.
    Fisch S; Bachner-Hinenzon N; Ertracht O; Guo L; Arad Y; Ben-Zvi D; Liao R; Schneiderman J
    J Am Heart Assoc; 2020 May; 9(10):e014761. PubMed ID: 32378446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.